The goal of this clinical trial is to learn if Zanubrutinib, Rituximab, and Lenalidomide works to treat marginal zone lymphoma as the first-line therapy. It will also learn about the safety of the treatment. The main questions it aims to answer are Does the combined therapy prolong patient survival? What medical problems do participants have when using this therapeutic approach? Researchers will observe the treatment to see if it works well than conventional therapies.
Participants will Administer drugs as required by the protocol Visit the clinic regularly for checkups and tests Keep a diary of their symptoms, examination and laboratory test indicators
18-75 years
Histologically confirmed MZL in untreated stage III or IV and needed for therapy as determined by the treating physician
ECOG performance status 0-2
Expected survival ≥ 6 months
Pregnant or lactating women
Active central nervous system lymphoma
Previous anti-tumor treatment
A severe immediate-type hypersensitivity reaction history for any of the drugs used in this study
Zhengzhou University
Lead sponsor
The First Affiliated Hospital of Zhengzhou University
Sponsor institution